LogicBio Therapeutics (OTCMKTS:LOGC) Releases Earnings Results, Misses Estimates By $0.10 EPS

Posted by James Conley on Aug 14th, 2026

LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10), Zacks reports. The firm had revenue of $33.60 million for the quarter, compared to analyst estimates of $22.48 million.

LogicBio Therapeutics Trading Up 0.5%

Shares of LOGC opened at $10.55 on Friday. The stock has a fifty day moving average of $9.39 and a two-hundred day moving average of $8.68. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.15 and a current ratio of 1.67. The company has a market capitalization of $482.45 million, a PE ratio of -9.68 and a beta of 2.02. LogicBio Therapeutics has a fifty-two week low of $7.05 and a fifty-two week high of $10.61.

Institutional Investors Weigh In On LogicBio Therapeutics

An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. increased its holdings in shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Free Report) by 284.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 526,673 shares of the company’s stock after buying an additional 389,843 shares during the quarter. Goldman Sachs Group Inc. owned about 2.00% of LogicBio Therapeutics worth $3,676,000 as of its most recent filing with the Securities and Exchange Commission. 46.05% of the stock is currently owned by hedge funds and other institutional investors.

About LogicBio Therapeutics

(Get Free Report)

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.